Follow this innovation
[ via 
] [?]
Prevention of Cardiac Myopathy and Failure by Soluble Epoxide Hydrolase (sEH) Inhibitors
University of California System: University of California, Davis - UC Davis
posted on 02/21/2010
Hypertrophic cardiomyopathy is a very common cardiac disease that eventually results in cardiac failure, a serious condition affecting millions worldwide. Post cardiac failure, the condition is irreversible, and aside from cardiac transplantation, only symptomatic treatment is available to improve the symptoms. At present, there are few effective pharmacologic therapies cardiac arrhythmias associated with cardiomyopathy and heart failure. Available antiarrhythmic drugs carry a high risk of proarrhythmias and other systemic side effects.
Suggested Uses
Prevention and potential treatment of cardiomyopathies including, hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
Advantages
- A sEH drug can be easily administered and has few side effects;
- sEH inhibitors can also reverse pre-established cardiac hypertrophy; and,
- sEH inhibitors may also reduce the potential for cardiac arrhythmia associated with the hypertrophy.
Detailed Description
Researchers at the University of California, Davis have discovered a novel inhibitor of soluble epoxide hydrolase (sEH) that prevents the development of cardiac hypertrophy and resultant failure. UC Davis researchers have demonstrated this in a murine model of pressure-induced hypertrophy and failure using thoracic aortic banding.
File Number: 20691
Disease: Cardiovascular and Circulatory System
| Patent Number(s): | 2009/0216318 |
|---|---|
| Copyright: | ©2010-2012, The Regents of the University of California |
This innovation currently is not available for online licensing. Please contact Barbara Boczar at University of California System: University of California, Davis - UC Davis for more information.
request more info
ProfileFind more innovations
